InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 5,500+ research and publications.
Research title with ★ indicates InBody recommended paper.

Type 2 diabetes remission and substantial body weight reduction achieved with metformin and a sodium-glucose cotransporter 2 in

Sugiyama et al.
Used Parameters : BFM, PBF, SMM

Publication Year : 2020

Country : Japan

Journal : Cureus

The overall goal in the treatment of type 2 diabetes mellitus (T2DM) is remission. However, the effects of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) on remission of T2DM are unknown. We herein report a case involving an overweight 43-year-old man who completely recovered from T2DM after SGLT2i therapy (dapagliflozin at 5 mg/day). In the pretreatment period, he had a body mass index (BMI) of 26.0 kg/m 2, hemoglobin A1c (HbA1c) concentration of 10.3%, advanced insulin resistance, pancreatic β-cell dysfunction, and fatty …
Full text